Clinical Trials Logo

Clinical Trial Summary

Psychosocial stress leads to altered neuroendocrine functions, such as serotonergic dysfunction, as well as alterations of the autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis activity resulting in an imbalance between inhibitory and excitatory neurotransmitters. Clinical consequences include, inter alia, neurovegetative disorders, higher resting heart rate, hypertension, depressive symptoms, sleep disturbances, irregular body-weight changes, and insulin resistance. Poor dietary intake of the essential amino acid L-tryptophane as a precursor to 5-hydroxytryptamine (HT, serotonin) increases sensitivity to stress.

It is therefore the investigators hypothesis that daily oral administration of an amino acid mixture (dosage 3.8 g/day) with micronutrients specifically designed to decrease neurovegetative disorders will target these neuroendocrine and metabolic alterations in adults with psychosocial stress. The principal endpoints will be a decrease in points in the psychological-neurological questionnaire (PNF).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01425983
Study type Interventional
Source Kyberg Vital GmbH
Contact
Status Completed
Phase Phase 3
Start date March 2011
Completion date June 2012

See also
  Status Clinical Trial Phase
Completed NCT02825745 - Use of Betashot in Children and Adults With Epilepsy N/A
Recruiting NCT05518617 - Molecular and Functional Imaging in Monogenic PD.
Completed NCT01255358 - Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients Phase 2